Nachrichten zur BioMarin Pharmaceutical Aktie

BioMarin (BMRN) Gets FDA Nod for Hemophilia A Gene Therapy

Following FDAs approval, BioMarins (BMRN) Roctavian becomes the first gene therapy for treating severe hemophilia A....…

BioMarin Pharma Announces FDA Approval Of ROCTAVIAN Gene Therapy

WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced the FDA approved ROCTAVIAN gene therapy for the treatment of adults with…

FDA approves BioMarin’s gene therapy drug for hemophilia

BioMarin Pharmaceutical Inc. BMRN received Food and Drug Administration approval of its gene therapy Roctavian to treat hemophilia A, the…

BioMarin granted FDA nod for hemophilia A gene therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

New Gene Therapy Could Face Uphill Battle

The potential FDA approval of BioMarins gene therapy for hemophilia A would be a major win, but patient uptake could…

Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors

Um den gesamten Artikel unter globenewswire.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Is BioMarin (BMRN) Down 4% Since Last Earnings Report?

BioMarin (BMRN) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…

BioMarin to Participate in Bank of America 2023 Health Care Conference

SAN RAFAEL, Calif., May 4, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller, Executive Vice…

Form 10-Q BIOMARIN PHARMACEUTICAL For: Mar 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioMarin (BMRN) Q1 Earnings Top, Voxzogo Drives Sales

BioMarin (BMRN) reports encouraging first-quarter results, wherein both earnings and sales beat estimates. The rapid uptake of Voxzogo boosts revenues....…

BioMarin (BMRN) Reports Q1 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter…

BioMarin Pharmaceutical (BMRN) Q1 Earnings and Revenues Surpass Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of 39.53% and 4.17%, respectively, for the quarter ended March 2023. Do the…

Biomarin Pharmaceutical Inc. Q1 Profit Decreases, but beats estimates

WASHINGTON (dpa-AFX) - Biomarin Pharmaceutical Inc. (BMRN) revealed a profit for first quarter that decreased from the same period last…

BioMarin Pharmaceutical Non-GAAP EPS of $0.60 beats by $0.20, revenue of $596.4M beats by $26.01M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues

Growth of VOXZOGO® Accelerated with Rapid Uptake in Japan and Brazil Resulting in Increased Full-year 2023 Guidance Full-year 2023 Top-line…

Insiderhandel: Chief Executive Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 995.600$

Bienaime, Jean Jacques - Vorstand - Tag der Transaktion: 2023-04-10...…

Insiderhandel: Chief Executive Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 961.300$

Bienaime, Jean Jacques - Vorstand - Tag der Transaktion: 2023-04-06...…

Insiderhandel: Aufsichtsrat verkauft Aktien von Biomarin Pharmaceutical im Wert von 825.265$

Lawlis, V Bryan - Aufsichtsrat - Tag der Transaktion: 2023-04-03...…

XETR : Deletion of Instruments from XETRA - 20.03.2023 -1-

The following instruments on XETRA do have their last trading day on 20.03.2023. Die folgenden Instrumente auf XETRA haben ihren letzten…

Insiderhandel: Chief Executive Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 723.600$

Bienaime, Jean Jacques - Vorstand - Tag der Transaktion: 2023-03-13...…

Insiderhandel: Chief Executive Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 1.384.200$

Bienaime, Jean Jacques - Vorstand - Tag der Transaktion: 2023-03-10...…

BioMarin (BMRN) Provides FDA Filing Update for Gene Therapies

The FDA accepts BioMarins (BMRN) label-expansion filing for Voxzogo to treat children under five years with achondroplasia. The agency extends…

Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock?

Investors need to pay close attention to BioMarin Pharmaceutical (BMRN) stock based on the movements in the options market lately....…

BioMarin seeks FDA nod to expand use of its Voxzogo treatment in children under five

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

FDA now set to decide on BioMarin’s hemophilia drug by June 30

BioMarin Pharmaceutical Inc. BMRN said Tuesday that the Food and Drug Administration pushed back the deadline to make a decision…

BioMarin: FDA Extends Review Of BLA For Roctavian Gene Therapy For Severe Hemophilia A

WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) said Monday that it received notice from the U.S. Food and Drug Administration…

Why BioMarin Shares Are Plunging Today?

Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are falling in reaction to positive data from BridgeBio Pharma Inc's (NASDAQ: BBIO) dwarfism drug, heating the…

BridgeBio Stock Surges on Dwarfism Drug Data. Its Bad News for BioMarin.

An experimental drug showed an annualized improvement of height velocity of 3.03 centimeters per year in a study including 10…

BioMarin’s stock falls after another company’s dwarfism drug moves into Phase 3 clinical trials

Shares of BioMarin Pharmaceutical Inc. BMRN were down about 6.0% in premarket trading on Monday after BridgeBio Pharma Inc. BBIOshared…

Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics

The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended December 2022, but…

BioMarin Pharmaceutical (BMRN) Q4 Earnings Lag Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of -7.69% and 0.69%, respectively, for the quarter ended December 2022. Do the…

Form 10-K BIOMARIN PHARMACEUTICAL For: Dec 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Biomarin Pharmaceutical Inc. Q4 Earnings Summary

WASHINGTON (dpa-AFX) - Below are the earnings highlights for Biomarin Pharmaceutical Inc. (BMRN):Earnings: -$0.2 million in Q4 vs. -$57.9 million…

BioMarin Pharmaceutical GAAP EPS of $0.00 beats by $0.07, revenue of $537.5M misses by $0.74M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioMarin Pharmaceutical: Coverage aufgenommen

New York (www.aktiencheck.de) - Rating-Update: David Lebowitz, Analyst der Citigroup, nimmt die Coverage für die Aktie von BioMarin Pharmaceutical Inc. (ISIN:…

BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth

BioMarin (BMRN) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Insiderhandel: Chief Executive Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 654.900$

Bienaime, Jean Jacques - Vorstand - Tag der Transaktion: 2023-02-13...…

Insiderhandel: Chief Executive Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 1.651.650$

Bienaime, Jean Jacques - Vorstand - Tag der Transaktion: 2023-02-10...…

Insiderhandel: EVP, Chief Commercial Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 5.669.134$

Ajer, Jeffrey Robert - Vorstand - Tag der Transaktion: 2023-01-25...…

Insiderhandel: Chief Executive Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 1.115.500$

Bienaime, Jean Jacques - Vorstand - Tag der Transaktion: 2023-01-17...…

Insiderhandel: Chief Executive Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 1.122.500$

Bienaime, Jean Jacques - Vorstand - Tag der Transaktion: 2023-01-13...…

Insiderhandel: EVP, Chief Financial Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 286.250$

Mueller, Brian - Vorstand - Tag der Transaktion: 2023-01-13...…

Form 8-K BIOMARIN PHARMACEUTICAL For: Jan 09

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

6 Analysts Have This to Say About Biomarin Pharmaceutical

Latest Ratings for BMRN DateFirmActionFromTo Feb 2022Piper SandlerMaintainsOverweight Nov 2021Credit SuisseMaintainsOutperform Nov 2021Morgan StanleyMaintainsEqual-Weight View…

BioMarin Pharmaceutical: Kursziel erhöht

Charlotte (www.aktiencheck.de) - Rating-Update: Geoff Meacham, Analyst von BofA Securities, stuft die Aktie von BioMarin Pharmaceutical Inc. (ISIN: US09061G1013, WKN 924801,…

Thinking about trading options or stock in Biomarin Pharmaceutical, Docusign, Apple, MicroStrategy, or Allstate Corp?

NEW YORK, Jan. 5, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BMRN, DOCU, AAPL, MSTR, and ALL. Click…

BioMarin Pharmaceutical: "overweight"

Minneapolis (www.aktiencheck.de) - Rating-Update: Christopher Raymond, Analyst von Piper Sandler, stuft die Aktie von BioMarin Pharmaceutical Inc. (ISIN: US09061G1013, WKN 924801,…

European Medicines Agency Validates Application for Extension of Indication for VOXZOGO® (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2

BioMarin Submits Supplemental New Drug Application to U.S. Food and Drug Administration to Expand Label to Treat Children with Achondroplasia…